CATX Perspective Therapeutics, Inc.

AMEX
$0.92

Perspective Therapeutics, Inc. (CATX) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.26 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +8.0% since its last earnings release on November 9, 2026.

Perspective Therapeutics Missed Consensus Estimates
Monday, November 9, 2026 · 4:30 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 4:20 PM ET
Earnings Whisper
-
vs ($0.26)
Rev est $200K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.84

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Perspective Therapeutics, Inc.

Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.